Clinical Trial Update: IT-hu14.18-IL2 With Radiation, Nivolumab and Ipilimumab for Melanoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluates IT-hu14.18-IL2 with radiation, nivolumab and ipilimumab for melanoma; the study is sponsored by the University of Wisconsin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• IT-hu14.18-IL2
• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: University of Wisconsin, Madison | Conditions: Melanoma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING